Indeed, it has been demonstrated in preclinical trials that Vitamin C is enough to sensitize KRAS-mutant cells to cetuximab in CRC [151] and Erlotinib in lung cancer [200], both in vivo and in vitro. Here, KRAS is linked to colorectal carcinoma.